Hos patienter med kronisk hepatit B- infektion kunde ingen skillnad noteras mellan lamivudin - och placebobehandlade patienter avseende frekvensen av dessa medicinska incidenter. ###>In patients with chronic hepatitis B there was no observed difference in incidence of these events between placebo and lamivudine treated patients.